Novo Integrated Sciences, Inc.

NVOS Healthcare Medical Care Facilities

Novo Integrated Sciences, Inc.’s revenue for fiscal 2024 (year ended August 2024) was $13.3 million, up 5.75% from fiscal 2023. Revenue growth for five consecutive years.

0.00 0.00 NaN
Market cap
$730.0K
P/E
0.0×
Fwd P/E
−10.1×
Dividend yield
—
F-score
3/9
Altman Z
−4.39
Beneish M
−4.29
Dividend safety
n/a
Aug '24 May '24 Feb '24 Nov '23 Older periods
ROE
(82.67%) (135.33%) (49.47%) (63.50%)

+8 more TTM periods

Piotroski F-Score
3 2 3 5
ROA
(47.76%) (68.46%) (33.83%) (37.23%)
ROIC
(42.44%) (71.21%) (26.28%) (26.49%)
Return on Tangible Assets
398.81% 214.21% (3,945.22%) (1,163.58%)
Average Days of Receivables
86.54 88.98 85.58 103.08
Free Cash Flow per Share
(0.28) (0.26) (0.28) (0.25)
Free Cash Flow
(5.12) (4.80) (4.95) (4.12)
Other line items

Show all line items

Columns are period end dates